John E. Imhoff - 18 Dec 2025 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Role
Director, 10%+ Owner
Signature
/s/ John E. Imhoff
Issuer symbol
GTHP
Transactions as of
18 Dec 2025
Net transactions value
$0
Form type
4
Filing time
12 Mar 2026, 19:52:25 UTC
Previous filing
05 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Imhoff John E Director, 10%+ Owner 5853 PEACHTREE CORNERS EAST, SUITE B, PEACHTREE CORNERS /s/ John E. Imhoff 12 Mar 2026 0001348439

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHP Common Stock Conversion of derivative security +195,460 +1% $0.0700* 19,658,955 18 Dec 2025 Direct F1
transaction GTHP Common Stock Other +25,338 +0.13% 19,684,293 05 Jan 2026 Direct F2
transaction GTHP Common Stock Conversion of derivative security +312,720 +1.6% $0.0700* 19,997,013 02 Feb 2026 Direct F3
transaction GTHP Common Stock Exercise of in-the-money or at-the-money derivative security +500,000 +2.5% 20,497,013 25 Feb 2026 Direct F4
transaction GTHP Preferred Series E Stock Other -100 -100% 0 27 Feb 2026 Direct F5
transaction GTHP Common Stock Other +400,000 +2% 20,897,013 27 Feb 2026 Direct F5
transaction GTHP Common Stock Conversion of derivative security +156,086 +0.75% $0.0700* 21,053,099 27 Feb 2026 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHP Convertible Promissory Note Conversion of derivative security -195,460 -57% 150,000 18 Dec 2025 Common Stock 195,460 $0.0700 Direct F1
transaction GTHP Convertible Promissory Note Conversion of derivative security -312,720 -71% 130,000 02 Feb 2026 Common Stock 312,720 $0.0700 Direct F3
transaction GTHP Warrants Other -500,000 -100% 0 25 Feb 2026 Common Stock 500,000 $0.6500 Direct F4
transaction GTHP Warrants Other +500,000 500,000 25 Feb 2026 Common Stock 500,000 $0.6500 Direct F4
transaction GTHP Warrants Other -500,000 -100% 0 25 Feb 2026 Common Stock 500,000 $0.5000 Direct F4
transaction GTHP Warrants Other +500,000 500,000 25 Feb 2026 Common Stock 500,000 $0.2000 Direct F4
transaction GTHP Warrants Exercise of in-the-money or at-the-money derivative security -500,000 -100% 0 25 Feb 2026 Common Stock 500,000 $0.2000 Direct F4
transaction GTHP Convertible Promissory Note Conversion of derivative security -156,086 -57% $0.0700* 120,000 27 Feb 2026 Common Stock 156,086 $0.0700 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.
F2 These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157.
F3 On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.
F4 During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.
F5 On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.
F6 On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.